Financial Comparison: EOM Pharmaceutical (OTCMKTS:IMUC) & Metagenomi (NASDAQ:MGX)

EOM Pharmaceutical (OTCMKTS:IMUC) and Metagenomi (NASDAQ:MGX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Risk & Volatility

EOM Pharmaceutical has a beta of 0.52, suggesting that its stock price is 48% less volatile than the S&P 500. Comparatively, Metagenomi has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for EOM Pharmaceutical and Metagenomi, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
EOM Pharmaceutical	0	0	0	0	0.00
Metagenomi	1	0	3	1	2.80

Metagenomi has a consensus target price of $10.00, indicating a potential upside of 589.66%. Given Metagenomi’s stronger consensus rating and higher probable upside, analysts clearly believe Metagenomi is more favorable than EOM Pharmaceutical.

Profitability

This table compares EOM Pharmaceutical and Metagenomi’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
EOM Pharmaceutical	N/A	N/A	N/A
Metagenomi	-287.06%	-43.19%	-31.06%

Valuation & Earnings

This table compares EOM Pharmaceutical and Metagenomi”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
EOM Pharmaceutical	N/A	N/A	-$1.89 million	N/A	N/A
Metagenomi	$52.29 million	1.04	-$78.06 million	($2.40)	-0.60

EOM Pharmaceutical has higher earnings, but lower revenue than Metagenomi.

About EOM Pharmaceutical

Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.

About Metagenomi

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.